trending Market Intelligence /marketintelligence/en/news-insights/trending/D1OvnyT_N3AZaHfZaFyl5Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Eidos Therapeutics appoints former Portola executive to board

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Eidos Therapeutics appoints former Portola executive to board

Eidos Therapeutics Inc. appointed William Lis to its board, effective Dec. 4.

Lis recently was CEO and a director of biopharmaceutical company Portola Pharmaceuticals Inc.

Additionally, Hoyoung Huh stepped down as a director of Eidos.

Eidos Therapeutics is a clinical-stage biopharmaceutical company that develops drugs to treat diseases caused by the neurodegenerative disease transthyretin amyloidosis.